Aptinyx Stock Price - APTX

0.00 (0.00%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Aptinyx Inc APTX NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.02 0.58% 3.47 3.41 3.58 3.45 3.45 23:59:39
Bid Price Ask Price Spread Spread % News
3.00 5.78 2.78 48.1% 2 -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
901 195,776 $ 3.51 $ 688,085 478,186 2.61 - 6.00
Last Trade Time Type Quantity Stock Price Currency
15:59:36 3,480 $ 3.47 USD

Aptinyx Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 157.44M 45.37M $ -53.28M -2.79 - 43.98M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% 8.00 4.10%

more financials information »

Aptinyx News

Loading Messages....

Latest APTX Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical APTX Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week3.763.873.403.54314,337-0.29-7.71%
1 Month3.905.303.404.29541,742-0.43-11.03%
3 Months3.185.302.903.96320,4620.299.12%
6 Months3.155.302.613.79200,4120.3210.16%
1 Year5.506.002.613.90246,361-2.03-36.91%
3 Years17.4032.252.618.17231,250-13.93-80.06%
5 Years17.4032.252.618.17231,250-13.93-80.06%

Aptinyx Description

Aptinyx Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. Its pipeline products are NYX-2925, NYX-458, and NYX-783. NYX-2925 is a novel, oral, small-molecule NMDA receptor modulator in clinical development as a therapy for chronic pain. NYX-2925 works by enhancing synaptic plasticity, a mechanism uniquely suited to addressing chronic pain, and NYX-783 is an NMDA receptor modulating small molecule in clinical development as a therapy for post-traumatic stress disorder.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.